If you could only know one gene in your genome, a strong case exists for APOE. It is the single most important genetic risk factor for late-onset Alzheimer's disease — the form that accounts for about 95% of all Alzheimer's cases. It influences your cardiovascular health, your cholesterol metabolism, and potentially your response to head injuries. And unlike most genetic risk factors that nudge your odds by single-digit percentages, APOE moves the needle dramatically.
But here's what most coverage gets wrong: APOE is not a binary "Alzheimer's gene." It comes in three versions, two of which most people carry, and your combination of those versions creates a spectrum of risk — not a yes-or-no diagnosis. Understanding that spectrum is the difference between useful genetic knowledge and unnecessary panic.
The Three Alleles: A Quick Primer
The APOE gene encodes a protein called apolipoprotein E, which helps transport cholesterol and other fats through your bloodstream and brain. The gene comes in three common variants — called alleles — that differ by just one or two amino acids at positions 112 and 158:
ε2 contains cysteine at both positions. It binds poorly to LDL receptors, which paradoxically tends to be protective against Alzheimer's. About 7% of the population carries at least one copy.
ε3 has cysteine at position 112 and arginine at 158. It is considered the "neutral" baseline and is by far the most common allele, carried by roughly 78% of people worldwide.
ε4 contains arginine at both positions. It is the high-risk allele for Alzheimer's, carried by about 20% of Americans — but found in approximately 60% of all Alzheimer's patients.
Since you inherit one copy from each parent, your APOE genotype is one of six possible combinations: ε2/ε2, ε2/ε3, ε2/ε4, ε3/ε3, ε3/ε4, or ε4/ε4.
Risk by Genotype
The clinical data on APOE and Alzheimer's risk is extensive. Here's what the research shows for lifetime risk by age 85:
| Genotype | Population % | AD Risk by 85 | Relative Risk vs ε3/ε3 |
|---|---|---|---|
| ε2/ε2 | ~0.5% | <5% | ~0.6× (protective) |
| ε2/ε3 | ~11% | <10–15% | ~0.6× (protective) |
| ε3/ε3 | ~60% | 10–15% | 1× (baseline) |
| ε2/ε4 | ~2% | ~15–20% | ~2.6× |
| ε3/ε4 | ~21% | 20–25% | ~3.2× |
| ε4/ε4 | ~2–3% | 30–55% | ~10–15× |
A few things jump out from this data. First, even the highest-risk genotype (ε4/ε4) is not deterministic. At 30–55% lifetime risk, roughly half of ε4 homozygotes will not develop clinical Alzheimer's by age 85. Second, the ε2 allele is genuinely protective — ε2 homozygotes showed a 46% reduction in odds compared to ε3 carriers in large neuropathology studies. Third, about one in five people carries at least one ε4 copy, making this a common variant with real clinical significance, not a rare mutation.
Beyond Alzheimer's: What Else APOE Affects
Alzheimer's risk dominates the APOE conversation, but this gene does other things worth knowing about.
Cardiovascular Health
The ε4 allele is associated with higher LDL cholesterol and increased susceptibility to cardiovascular disease. The ε2 allele tends to raise triglycerides but lower LDL. If you carry ε4, your lipid management strategy — diet, exercise, and potentially statins — becomes more important, and your physician may want to monitor your lipid panel more closely.
Age of Cognitive Onset
For people who do develop Alzheimer's, APOE genotype influences when. The mean age of clinical onset for ε4/ε4 homozygotes is around 68, compared to 84 for people without any ε4 copies — a roughly 16-year difference. This doesn't mean symptoms are guaranteed at 68; it means that among those who develop AD, ε4 homozygotes tend to develop it earlier.
Head Injury Response
Emerging research suggests ε4 carriers may have worse outcomes after traumatic brain injury and may be more susceptible to chronic traumatic encephalopathy (CTE). If you're an ε4 carrier involved in contact sports, this is worth discussing with your physician.
Why Whole Genome Sequencing Catches What Chips Miss
The two SNPs that define your APOE allele (rs429358 and rs7412) are on most genotyping arrays, so even a basic 23andMe or AncestryDNA test can theoretically identify your APOE genotype. Some DTC providers include it in health reports; others have removed it due to the anxiety it generates.
But APOE does not act alone. Recent research has identified modifying variants — like the R145C variant on the ε3 allele — that can nearly triple Alzheimer's risk in ε3/ε4 carriers of African ancestry. These modifiers don't show up on genotyping chips. They require whole genome sequencing.
There is also a broader context. APOE interacts with dozens of other Alzheimer's-associated loci (TREM2, CLU, PICALM, BIN1, among others), and your overall polygenic risk profile matters more than any single gene. A 30× whole genome sequence captures all of these variants in a single test, alongside pharmacogenomic markers that affect which medications work best for you.
Know Your APOE Status
Dante Labs' 30× whole genome sequencing reveals your complete APOE genotype plus thousands of other health-relevant variants — all from a simple saliva sample.
Get Your Genome Sequenced → Use code GENOME for 10% offWhat to Do With Your APOE Result
Let's say you've been sequenced and you know your APOE genotype. Now what? The answer depends on which combination you carry.
If You Carry ε3/ε3 (Most People)
You are at baseline population risk. No special action is needed beyond the brain-health fundamentals that benefit everyone: regular cardiovascular exercise, adequate sleep, social engagement, cognitive stimulation, and a Mediterranean-style diet. These aren't APOE-specific recommendations — they are the foundation of brain health regardless of genotype.
If You Carry One ε4 Copy (ε3/ε4 or ε2/ε4)
Your risk is elevated but not dramatically. Prioritize the same lifestyle factors above, but with more urgency. Pay closer attention to cardiovascular health, since ε4 affects both brain and heart. Consider establishing a cognitive baseline with a neuropsychologist in your 50s so you have a reference point for comparison. Discuss lipid management with your primary care physician.
If You Carry Two ε4 Copies (ε4/ε4)
This is the genotype that generates the most anxiety, and understandably so. But remember: 30–55% lifetime risk means 45–70% of ε4/ε4 carriers will not develop Alzheimer's by 85. The lifestyle interventions listed above become especially important. Consider connecting with a genetic counselor to discuss the implications, especially for family planning and long-term care planning. Ask your physician about emerging therapeutics — anti-amyloid antibodies like lecanemab have shown clinical benefit, and new APOE-targeted therapies are in clinical trials.
If You Carry ε2 (ε2/ε3 or ε2/ε2)
You have a degree of protection, but not immunity. The ε2 allele reduces Alzheimer's risk by roughly 40–50% relative to ε3. Worth knowing, but don't treat it as a license to neglect brain health.
What APOE Testing Cannot Tell You
APOE genotyping is a risk assessment tool, not a diagnostic test. There are important limitations to understand clearly.
It cannot tell you whether you will definitely develop Alzheimer's. Even ε4/ε4 is not deterministic. It cannot tell you when symptoms might begin. It provides statistical risk ranges, not personal timelines. It cannot replace clinical evaluation — if you're experiencing cognitive changes, a neurologist and neuropsychological testing are what you need, not another look at your APOE genotype.
APOE genotyping also has poor predictive value at the individual level, which is why it is not routinely offered in clinical settings. Population-level statistics don't translate neatly to individual predictions, and current U.S. law (GINA) does not prevent discrimination from life insurance and long-term care insurance providers based on APOE results. If you're considering purchasing these policies, you may want to do so before learning your APOE genotype.
APOE is the single most important common genetic risk factor for Alzheimer's disease. The ε4 allele increases risk in a dose-dependent manner (one copy ≈ 3× risk, two copies ≈ 10–15× risk), while ε2 is protective. But even the highest-risk genotype is not a diagnosis — it's a probability shift.
The most actionable response to any APOE result is the same: prioritize cardiovascular exercise, sleep, social engagement, and metabolic health. Knowing your genotype adds urgency, not a fundamentally different playbook.
Whole genome sequencing provides your APOE status alongside the broader polygenic context and pharmacogenomic data that chip-based tests miss.
Further Reading
If APOE has you thinking about the genetics of disease risk, our genome testing and cancer risk guide covers actionable genes like TP53, BRCA1/2, and Lynch syndrome markers. For understanding what your raw genome files actually contain, see our FASTQ, BAM, and VCF explainer. And if pharmacogenomics — how your genes affect drug metabolism — interests you, our pharmacogenomics deep dive covers the CYP enzymes that matter most.